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ABSTRACT
THE ASSOCIATION BETWEEN MEASURES OF ADIPOSITY AND
ANOVULATION IN WOMEN WITH REGULAR MENSTRUAL CYCLES
MAY 2011
NICOLE ASH, B.S., RUSSELL SAGE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Brian Whitcomb

Anovulation accounts for approximately 12 percent of all female infertility in the
United States. Prior studies suggest women with high body mass index (BMI) have an
increased risk of infertility, particularly obese women with abnormal cycle lengths. To
date no studies have examined the relationship between measures of adiposity, including
BMI and percent body fat measured by DXA scan (%BF), and anovulation among
women with regular menstrual cycles assessed with biomarkers. We evaluated this
association using data from the BioCycle study, a prospective cohort of 259 women with
regular menstrual cycles. All measures of adiposity and covariates were collected at
baseline. Anovulation was assessed via luteinizing hormone and progesterone levels in
urine samples collected 16 times throughout two menstrual cycles.
A total of 34 women had at least one anovulatory cycle during the study.
Unadjusted models for BMI show a significant decrease in risk comparing highest BMI
quartile to the lowest, (OR: 0.29; 95% CI .090-.968). Once multivariable logistic
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regression was used to adjust for age no significant associations were found in any BMI
quartile, but point estimates did not change significantly. Similar trends were found using
other measures of adiposity. Results show that there is a non-significant inverse trend
between adiposity and anovulation in healthy women with regular menstrual cycles. This
relationship can possibly be explained by age due to the influence of time since menarche
(TSM). Further research is needed to examine this relationship.
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CHAPTER I
INTRODUCTION

According to the clinical definition, infertility occurs when a couple, not using
contraception, is unable to become pregnant after twelve or more months of trying (1). In
2002, the National Survey of Family Growth estimated that 7.4% or 2.1 million women
in the US are infertile (1). Infertility can be divided into four categories: female
infertility, male infertility, female and male combined infertility, and unknown cause. It is
estimated that somewhere between 50-60% of infertility cases are due to female
infertility and 30-40% are due to both male and female infertility problems (2).
Female infertility can be further subdivided into 8 categories: hypothalamicpituitary factors, ovarian factors, tubal/peritoneal factors, uterine factors, cervical factors,
vaginal factors, genetic factors, and unknown etiology. It is estimated that approximately
12% of all female infertility can be attributed to ovarian dysfunction; either the
inadequate formation of the corpus luteum or inability to produce an oocyte (2). Women
with regular menstrual cycles may have infertility and not be aware of the fact until they
try to become pregnant because anovulatory cycles are asymptomatic.
Increased adiposity may contribute to anovulation through disturbances in the
hypothalamic-pituitary-ovarian (HPO) axis, which regulates reproductive hormones.
There is research supporting the association between obesity and the disruption in
ovulation via two mechanisms: 1) hyperandrogenism and 2) insulin resistance (3, 4).
To date no epidemiologic studies have evaluated the association between
adiposity and anovulation in a population of women with regular menstrual cycles using
1

biomarkers as a measure for anovulation. However, studies using other measures of
infertility found an increase in risk between body mass index (BMI) and infertility (5-21).
In addition BMI has been found to affect fertility and response to fertility treatments
among women with reproductive disorders known to have anovulation as a symptom (2225). There also have been no studies that look at the association between multiple
measures of adiposity and anovulation using a better predictor of adiposity other than
BMI.
The identification of a modifiable factor such as adiposity, which can affect
fertility in all women, would give physicians other options prior to using infertility
treatment. Because anovulation is not easily detected without a biomarker it is important
that studies incorporate this measure. It is important to look at the normal menstrual cycle
in a healthy population in an attempt to identify possible changes that are present before a
woman needs to seek medical treatment for fertility problems. Therefore, we propose to
assess the relationship between BMI and anovulation using data from the BioCycle
Study, a prospective study of women who reported regular menstrual cycles and did not
have any other medical conditions that could affect ovulation. The participants had 16
visits during which both blood and urine were collected to measure multiple biomarkers
of menstrual cycle status and ovulation.
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CHAPTER II
PHYSIOLOGY OF ADIPOSITY AND ANOVULATION

There are a several biological mechanisms through which obesity may increase
the risk for anovulation. These mechanisms center on the HPO axis, which regulates both
the menstrual cycle and ovulatory function through a complex hormonal regulation
system. The two main disturbances to the HPO axis occur through either
hyperandrogenism or insulin resistance (4).
Hyperandrogenism is a biological condition where there is an excess production
or secretion of androgens, which include sex hormones (4). Adipose tissue has been
shown to have the potential to alter the secretion of sex hormones, given its essential role
in both androgen production and in the conversion of androgens into sex hormones (3).
Both androgen production and conversion affects the carrier protein sex hormone-binding
globulin (SHBG), an important hormone in the HPO axis (3, 4). Therefore, increased
adiposity can lead to an excess of adipose tissue, and in turn a disturbance in the
production of SHBG and other sex hormones, disrupting normal ovulatory function (3,
4). Therefore, it is plausible that adiposity contributes to ovulatory disorder.
In terms of a second mechanism, insulin resistance can lead to disturbance in
ovulatory function. The ovary is a target organ for insulin, requiring insulin to stimulate
the production of sex hormones (3). Adipose tissue affects insulin by producing
metabolites used in insulin secretion and metabolism. An increased amount of adipose
tissue may lead to an increased amount of insulin secreted and altered metabolism, in turn
causing insulin resistance throughout the body, thereby increasing the amount of
3

circulating insulin (4). This increased insulin level will negatively affect the ovary and its
sex hormone production, affecting the HPO axis and altering ovarian function. Therefore,
it is plausible that increased adiposity contributes to altered ovarian function.
In summary, there is biological evidence supporting the hypothesis that obesity increases
the risk for anovulation through the disruption of HPO axis by hyperandrogenism, and/or
insulin resistance.
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CHAPTER III
EPIDEMIOLOGY OF ADIPOSITY AND ANOVULATION

Approximately 21 studies have examined the association between obesity and
anovulation. Epidemiologic studies looking at BMI and anovulation measured by
biomarkers are sparse (9, 20, 23, 24). Previous studies have examined obesity and
fecundability, which is the probability for a woman to conceive during a given menstrual
cycle, (5, 6, 8, 17-19), and/or measuring time to pregnancy (TTP), which is a measure of
length of time it takes to become pregnant (7, 10-16, 21). These studies were conducted
among women diagnosed as subfertile (5-19), or women with polycystic ovarian
syndrome (PCOS) (22-25). To our knowledge no previous studies have looked at women
with regular menstrual cycles using the design we are interested in investigating.
Studies looking at BMI and fecundability or TTP have consistently observed
inverse associations (5-8, 14-16, 18, 21, 26). Other studies focusing on infertility, in a
case-control setting, found that those who had increased obesity measured by BMI were
at greater risk for infertility when compared to those who were fertile (10-13, 19).
Finally, studies conducted among women who have PCOS, a reproductive syndrome with
decreased ovulation as one of its main symptoms, found that there was an inverse
association between obesity and fertility (22-25). None of these studies were conducted
among women with regular menstrual cycles and none have measured ovulation using
biomarkers.
To our knowledge no studies to date have used multiple measures of adiposity in
an attempt to examine the amount of misclassification that can be introduced by only
5

using BMI. Previous studies have been done looking at measures other than the standard
BMI and anovulation (27) and have found a similar increased risk of anovulation with
increased adiposity. There have been studies that have looked at multiple measures of
adiposity as predictors for all cause mortality (28) and cardiovascular disease (29) and
were used to identify potential exposure variables reflecting adiposity.
In a large retrospective study among 10,903 Danish women who attended
antenatal care for their first planned and successful pregnancy, Jensen et al. assessed the
relationship between BMI and the fecundability odds ratio (FR) (5). Around the twentieth
week of gestation, women were asked the number of months they were trying to
conceive, if they had normal menstrual cycles, and their height and pre-pregnancy
weight. This information was then used to calculate TTP and BMI. After adjusting for
potential confounders, the fecundability for an “overweight” woman (defined as a BMI
>25 kg/m2) was decreased when compared to that of a “normal weight” woman (defined
as a BMI 20-25 kg/m2) (FR: 0.77; 95% confidence interval (CI) 0.70-0.84). Those with a
BMI below normal (<20 kg/m2) also had decreased fecundability as compared to normal
weight woman, although this was not statistically significant (FR: 0.95; 95% CI 0.901.01).
Due to the exclusion of non-pregnant women, those at highest risk were likely not
included. In addition, the measure of fecundability relied on each woman’s definition of
“trying” to become pregnant and is therefore subject to “wantedness bias” (30). This is
not an accurate measure of true ovulatory function, which is instead more accurately
measured through biomarkers that can assess the level of hormones and the point of
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ovulation in a woman’s cycle. This information would tell the researcher whether each
particular cycle was even ovulatory.
Rich-Edwards et al. were the first to examine the relationship between BMI and
infertility. In a nested case-control study using data from the Nurses’ Health Study II, the
authors defined cases as married nulliparous women who self reported inability to
become pregnant for at least one year because of an ovulatory disorder (n=2,527).
Controls were defined as married parous women who had no history of infertility
(n=46,718) (11). Self reported height and weight at age 18 was used to calculate BMI for
all study participants. After adjustment for potential confounders those in the highest
BMI category of ≥ 32 kg/m2 were at an almost three-fold increased risk for infertility
when compared to normal weight women (BMI category 20-21.9 kg/m2) (OR 2.7; 95%
CI 2.0-3.7). Women with a BMI above 23.9 kg/m2 also had a statistically significant
increase in risk.
Both exposure and outcome in this study could be misclassified due to data
collection technique. The self reported value of BMI makes nondifferential
misclassification of the exposure probable and this was not validated by the study. The
use of self reported ovulatory infertility has its limitations but was validated via a
secondary questionnaire and medical records. Among 40 out of 75 medical records
collected, a 95% confirmation rate was found.
Finally, Al-azemi et al. conducted a prospective study of 270 women who were
diagnosed with PCOS and seeking infertility treatment. The authors measured the
association between BMI and ovulation after medical induction (22). Women in the
highest BMI category (BMI ≥ 35 kg/m2) had a lower percentage of ovulation at 12
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months when compared to women in the BMI category of 18-24 kg/m2 (38.3% vs. 91.9%
p < 0.0001). The authors also found statistically significant differences in the 6 month
ovulation percentages for the highest BMI category and for the BMI category of 30-34
kg/m2 as compared to those in the BMI category of 18-24 kg/m2.
This study has limited generalizability because it was limited to a group of
women with a reproductive disorder that affects ovulation. The authors of the study did
not specify if they adjusted their findings for age. It is possible that the results they found
are confounded if they did not adjust for this important variable. It is important to know
the effect of BMI in healthy women because it can be used as a potential risk factor for
ovulatory problems.
In summary, no previous studies have prospectively assessed the association of
BMI and anovulation using biomarkers among a population of women with regular
menstrual cycles. However, prior epidemiological studies have found an inverse
association between BMI and fecundability and TTP (5-9, 12-21). Researchers have also
looked at women diagnosed with infertility and found this association (10, 11, 22-25).
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CHAPTER IV
SUMMARY

Infertility is estimated to affect 7.4% of the US population and 50-60% of cases
can be attributed to female infertility. Anovulation is an asymptomatic event that is
difficult to measure without biological measures (1, 2). BMI may lead to ovulation
disruption via hormonal disruptions of the HPO axis due to hyperandrogenism and
insulin resistance (3, 4).
Epidemiologic evidence suggests that a positive relationship between BMI and
decreased fecundity, increased TTP, and increased infertility (5-9, 12-21). Other studies
limited to women with reproductive disorders also found a relationship between BMI and
fertility (10, 11, 22-25). However, none of these studies have prospectively examined this
association among women with regular menstrual cycles using biomarkers to assess
ovulation.
Therefore, we examined the relationship between measures of adiposity and
anovulation using biomarkers in a population of women with regular menstrual cycles
and no history of other infertility problems.
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CHAPTER V
HYPOTHESIS AND SPECIFIC AIMS
Using a prospective cohort design, we evaluated the relationship between multiple
measures of adiposity and anovulation among women with regular menstrual cycles. The
following aim was addressed:
Specific Aim 1: To evaluate the association between BMI and anovulation in
women with regular menstrual cycles.
Hypothesis 1: Among adult females with regular menstrual cycles, those who
have higher BMI will have an increased risk for anovulation as compared to
those with normal BMI.
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CHAPTER VI
METHODS
Study Design and Population
Using a prospective cohort study design we evaluated the association between
BMI and anovulation. We also evaluated other measures of adiposity as possible
predictors of anovulation. We used data collected as part of the BioCycle Study
conducted at University of Buffalo in Buffalo, New York between 2005 and 2007.
A detailed description of the study population and design has previously been
published (26, 31-34). Briefly, healthy, regularly menstruating premenopausal women
were recruited from clinical practices, University of Buffalo health services, flyers, radio
& television ads, and local newspapers. The study was designed to include a total of 16
cycle visits over two menstrual cycles with visits usually scheduled to match key biologic
processes in menstrual cycle function. The initial schedule was based on a normal 28 day
cycle and had women come into the clinic on day 2, 7, 12, 13, 14, 18, 22, and 27. Fertility
monitors were used to modify the schedule of clinic visits based on the individual
woman’s cycle. At these visits, blood and urine samples were obtained and in-person
interviews were conducted.
Interested participants were scheduled for a screening visit where all exclusion
factors were measured. At the end of this exclusion visit a baseline/enrollment visit was
scheduled 1-2 weeks prior to the subjects’ next menstrual period. At this visit, physical
and anthropometric measures were taken, blood and urine samples were obtained, and
questionnaires were completed. The participants were given a daily diary and home
fertility monitor to take home with them and detailed instructions were provided for use
11

of both tools. The participants were then required to call the center on the first day of
their next period to schedule an appointment for the following day. All following visit
days were scheduled based on an algorithm using cycle length in attempt to time visits on
the correct days of the menstrual cycle (35). The participants began using the fertility
monitor on day 6 of their cycle and were instructed to come in if the monitor indicated
“peak fertility” on a day without a scheduled visit. If there was no positive indication on
the monitor by day 14, a visit was scheduled and the subject was instructed to continue to
monitor for 10 additional days. The fertility monitor was only used as a tool to schedule
visits close to ovulation. The measures from the monitor were not used in this study. A
total of 259 women with regular menstrual cycles participated in the study.
The following criterion was used as exclusion from the original study: DepoProvera, Norplant or intrauterine device use in the past 12 months; oral contraceptive or
other hormone supplement use in the past 3 months; planning to attempt to conceive in
the next 3 months; actively trying to conceive in the past 6 months; pregnancy currently
or in past 6 months; breast feeding in the last 6 months; abnormal pap smear in last 6
months with no subsequent normal results; laparoscopy confirmed endometriosis; current
uterine fibroids or removal in last 12 months; history of polycystic ovary disease; history
of Chlamydia infection or positive IgG at screening; untreated gynecological infection or
any infection in past 6 months; gynecological surgery in past year; sought treatment for
infertility ever; history or clinical signs of gynecological problems; infectious disease
treated by physician in past 6 months; treatment for allergies with chronic medication;
liver or kidney disease requiring treatment in past year; younger than 18 or older than 44;
psychiatric condition requiring medical therapy in last year; BMI <18 or >35.0 kg/m2
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measured in clinic; plan to consume restricted diet for weight loss or medical reasons in
next 3 months; gastrointestinal conditions associated with mal-absorption; unwilling to
stop regular intake of vitamin or supplements; chronic use of certain medications;
antibiotic use in past 3 months; history of chronic disease such as heart disease, diabetes
mellitus, cancer, inflammatory disease, autoimmune, liver or kidney, thyroid disease or
any other endocrine dysfunction; current treatment for anemia; history of alcohol abuse;
dependency disorder or substance abuse in past 30 days; self report of regular illicit drug
use in past 30 days; and diet high in phyto-estrogens.

Exposure Assessment
BMI was calculated using height and weight as measured by trained study personnel. The
measures were obtained at eight points in the cycle but only height and weight at baseline
visit was used. For our analysis, BMI was broken into quartiles. BMI was also be
analyzed continuously to evaluate a dose-response relationship (Table 1). We evaluated
the following measures of adiposity as possible predictors of anovulation, all of which
were measured at baseline: waist to hip ratio (WHR), percent body fat from Dual-energy
X-ray absorptiometry (DXA) scan, percent truncal fat from DXA, truncal to leg fat from
DXA, and total skinfold thickness. All measures were evaluated at as quartiles and
continuous variables (Table 1).

Validity of Exposure Assessment
To date DXA scan is considered one of the gold standards for measuring the true
amount of body fat a person has and the validity of the other measures of adiposity are
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often compared to this measure (36). The assessment of whether measured BMI is a true
measure of percent body fat has been assessed in previous studies (37). Blew et al.
measured the reliability between BMI calculated using height and weight measured by
the same instrument and percent body fat calculated from a DXA scan, which gives a true
measure of body fat. They found that among their population of women ages 40-66 there
was a high correlation between BMI and %body fat (r=0.81). Sensitivity for BMI was
25.6% and specificity was 99.3% using the NIH definition of obesity at 30 kg/m2 (37).
Taylor et al. measured the reliability between WHR and truncal fat measured by DXA
and found that among children 3-19 years old there was a correlation of value of 0.73
(38). Durin et al. found that when using total skin fold measurements that there was a
correlation value of 0.80 when comparing skinfold thickness to %body fat among young
women (39).

Outcome Assessment
Anovulation was identified using the biomarkers of LH and progesterone,
measured in urine collected at the 16 visits to the clinic during their cycle. A woman was
classified as anovulatory if peak progesterone concentration across the cycle was ≤
5ng/ML, reflective of corpus luteum failure, and there was no LH peak, reflective of
failure of oocyte being released, measured during at least one menstrual cycle. This
criterion was previously used in other studies using these data (26). The variable was
dichotomized into a “yes/no” variable (Table 1).
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Validity of Outcome Assessment
The validity of using LH urinary levels as a marker for ovulation has been shown
to have high validity. Guida et al. found that among 40 women ages 21-42 there was
100% correlation between urinary LH measured daily and ultrasound diagnosis of
ovulation with no difference in the accuracy and precision of LH and ultrasound (p <
0.05) (40). For this study, interassay coefficients of variation of LH were less than 4%
and for progesterone 14% (41, 42).

Covariate Assessment
Data for all covariates were collected via self report during in-person interviews
during the study (Table 1). We used baseline/enrollment measures of age; history of
smoking; history of alcohol use; stress using Cohen’s Perceived Stress Scale, a scale that
is used to measure participants perception of stress with high validity and reliability (43);
race; education; use of oral contraceptives; prior pregnancy; time since menarche (TSM)
and physical activity measured by the International Physical Activity Questionnaire
(IPAQ) score, a tool to quantify physical activity that has been shown to have high
validity (44). These factors have been found to be important covariates in prior studies of
fertility (5, 6, 9-11, 45).

Data Analysis Plan
Specific Aim: To evaluate the association between BMI and anovulation.
Univariate Analysis
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We calculated number and percentages of women in relation to the population
characteristics as well as their BMI categories and anovulation status (Table 1).
Bivariate Analysis
Covariates were cross tabulated with BMI quartiles (Table 2b) and with anovulation
status (Table 3) to evaluate potential confounders. Chi-square tests were used when cell
size is sufficient to assess homogeneity in the distribution. If the cell size was not
sufficient, Fishers exact test was used instead. P-values were derived from the Chi-square
tests for categorical variables and 2 sample t-tests for continuous variables.
Multivariable Analysis
Logistic regression was used to provide an unadjusted odds ratio and 95% confidence
interval for the association between BMI and anovulation (Table 4). Multivariable
logistic regression was then be used to model the relationship between BMI and
anovulation adjusting for potential confounders (Table 4). Covariates which change the
estimates for BMI by 10% or greater when added to the model were considered
confounders and retained in the multivariable model. Continuous variables were tested
for linearity in the logit and included as a continuous variable only if they met this
criterion. Generalized estimating equations (GEE) were used to examine the same
relationship by cycle instead of woman (Table 9). These models address the correlation
due to the multiple cycles per women. Sensitivity analysis was done to select an age
where the changes in the association between BMI and anovulation could be explained.
We stratified the data based on age, (Table 7). We also examined detailed information on
specific covariates based on the stratification groups (Table 5 & 6).
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Finally we examined other measures of adiposity to see if the association found
between BMI and anovulation was the same among all other measures. We first
examined the correlation between all measures of adiposity (Table 2a). We then chose
percent body fat (%BF) from DXA scan, which is a golden standard, to look at bivariate
relationships between %BF and covariates (Table 2c). Finally we looked at the
unadjusted and adjusted models of each measure of adiposity (Table 4).
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CHAPTER VII
SIGNIFICANCE

To date no studies have evaluated the association between adiposity and
anovulation in women with regular menstrual cycles. These women are an important
population to examine because if there is a difference in their risk for anovulation than
they can be identified prior to seeking medical help for fertility problems. Given that
adiposity is potentially modifiable risk factor for women who are having trouble
conceiving, research to evaluate this relationship is pertinent. Results from this study will
further research in this area and may suggest a way to increase conception potential
among women with regular menstrual cycles.
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CHAPTER VIII
HUMAN SUBJECT PROTECTION

The BioCycle study was approved by the Institutional Review Boards of
University of Buffalo, the National Institutes of Health, and University of Massachusetts.
All participants were required to sign an informed consent statement indicating that they
understood the study requirements, that they were under no obligation to participate, and
that they could withdraw at any time.
Every effort is made to ensure that confidential information remains secure. Study
personnel were trained in privacy protocols and all study records are kept under lock and
key at the original study site. Computer files are kept on a secure server that is password
protected, with only study personnel able to get access to these files once permission is
granted from the study coordinator.
The known risk to participants is adverse reactions to blood draws during the
study visit, which all participants were informed of before signing the consent. There is
also a possibility that potentially sensitive information about the participants could be
obtained if there were to be a confidentiality breach. Given that all study personnel are
trained in privacy procedures, this is unlikely to occur. The only known benefit to the
participants in the study was the knowledge that they would be advancing science in the
area of women’s reproductive health.
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CHAPTER IX
PERMISSION TO ACCESS DATA

I, Nicole Ash received permission to use the BioCycle Study database from Brian
W. Whitcomb, BioCycle Study investigator. The BioCycle Study was approved by IRBs
at the University at Buffalo and the National Institutes of Health. Use of the BioCycle
Study database for research at UMass was approved by the School of Public Health and
Health Sciences IRB.
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CHAPTER X
RESULTS

Study population characteristics can be seen in Table 1. Women in the study were
more likely to be white, non-smokers who had at least a college education, were past
users of oral contraceptives and nulliparous. The average age of the population was 27.29
(SD ±8.2) years with an average BMI of 24.08kg/m2 (SD ±3.9).
Table 2a shows the correlation between each of the measures of adiposity using
Pearson’s product-moment correlation calculation. Each of the correlations was
statistically significant, with all measures being highly correlated except for WHR.
Distribution of participants by BMI Quartile and %BF quartile can be seen in
Table 2b and Table 2c respectively. The only covariate to differ significantly between the
quartiles of BMI was age (p=0.04). The same was true for %BF.
Table 3 shows the distribution of participants by anovulatory status. A total of 34
women or 13% had at least one anovulatory cycle. There was a significant difference in
age between the ovulatory women versus the anovulatory women. Ovulatory women had
an average age 28.28 (SD ±8.3) years verses the anovulatory 20.79 (SD ±2.9)
(p=<0.001). Anovulatory women also differed significantly from ovulatory women in
regards to education level, with 20.6% of anovulatory women being college graduates
compared to 52% of ovulatory women (p=<0.001). Previous pregnancy also differed
between the two groups with 43.4% of ovulatory women having a previous pregnancy
compared with 14.3% of anovulatory (p=0.04). Finally, past oral contraceptive also
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differed between the two groups. 57.4% of the ovulatory women had used oral
contraceptives in the past compared with 37.5% of the anovulatory women (p=0.03).
In unadjusted analysis, BMI quartiles 2 and 3, along with the continuous measure
of BMI, were not significantly associated with anovulation (Table 4). Women in BMI
quartile 2 had a non-significant 29% decreased risk for anovulation compared with
women in BMI quartile 1 (95% CI: .28-1.82). The odds ratio comparing BMI quartile 3
to BMI quartile 1 was the same. When BMI quartile 4 was compared to BMI quartile 1,
women in quartile 4 had a significant 71% decreased risk for anovulation (95% CI: .0900.986). Looking at BMI as a continuous variable the unadjusted odds ratio (OR) was
0.91 (95% CI: 0.82-1.01) for each one unit increase in BMI. Once adjusted for age, the
OR for women in the second BMI quartile compared to the first was 0.66 (95% CI: 0.241.80), while the OR for women in the third quartile compared to the first was 0.73 (95%
CI: 0.26-2.01). The OR for the fourth quartile compared to the first became nonsignificant 0.38 (95% CI: .106-1.33). We also looked at BMI quintiles and sextiles and
found similar non-significant inverse trend (Table 8). The analysis using GEE examining
cycles instead of women found the same non-significant trend (Table 9). We found
similar results among all measures of adiposity with no significant relationships (Table
4).
We were interested in the impact age had on the BMI-anovulation relationship.
Sensitivity analyses were done, and age of 22 years was identified as the point where
those above and below had differenced in both their BMI and anovulation status. We
stratified the women into those less than 22 years of age (Table 5) and greater than or
equal to 22 years (Table 6). This showed that women less than 22 who were anovulatory
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were more likely to be in BMI quartile 1 and have a less time since menarche (TSM). An
unadjusted model of just TSM and anovulation found a significant 31% decrease in risk
of anovulation for every year since menarche (95% CI: 0.51-0.94). Women who were 22
or older and anovulatory also were more likely to be in BMI quartile 1 but had a much
longer TSM. TSM in this group was not significantly related to anovulation (OR 0.71;
95% CI: 0.50-1.00). When the multivariable models were examined separating the
women into these two groups the non-significant trend was still seen but was more
pronounced in those less than 22 years (Table 7).
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CHAPTER XI
DISCUSSION

In this study of 259 healthy women with regular menstrual cycles, we found no
significant associations between adiposity and anovulation, but did find a non-significant
inverse trend in the data. We found that women who were younger than 22 years were the
ones who had the most cases of anovulation. These women were also found
predominately in the first BMI quartile and to have the shortest time since menarche.
Our non-significant results of BMI and anovulation, among women with regular
menstrual cycles, is different than previous findings for fecundability and TTP (5-9, 12,
12-21) and women with diagnosed infertility (10, 11, 22-25). We hypothesized that we
would see the same relationship in this population of healthy women with regular
menstrual cycles as other studies found. However, we found no significant association
between adiposity and anovulation in this population even after adjusting for age. We did
have a small sample size, limiting power for the study. We had 80% power to detect an
odds ratio of 3.25 so it is possible that if we had a larger sample size we may have been
able to detect a smaller difference in the groups.
Based on the findings it could be hypothesized that among young healthy women
anovulation is strongly associated with age and time since menarche and is minimally
influenced by adiposity. Among women ≥ 22 years there were very few anovulatory
cycles limiting our ability to evaluate the association with BMI.
The range of BMI in our study was also limited by the exclusion criteria. We had
no individuals that were over 35 kg/m2, which excluded those in the higher BMI ranges
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and could have also excluded those who would be most likely to be at risk for
anovulation. Some of the previous studies found a U-shape association with BMI and it is
possible that since we don’t have those in the largest BMI categories we could only be
seeing part of this U-shape design and if we include women in with higher BMI’s then
we may have found this U-shape in our results also.
Further research would need to be done to examine these two hypotheses. A study
which included a wider range of BMI, along with increased numbers of women, could be
beneficial to look closer at this relationship and have the statistical power to detect small
differences that may be present.
It is possible that our results were affected by bias. Nondifferential
misclassification of exposure may arise if women were to report their own height and
weight used to calculate BMI. This type of misclassification, would underestimate any
association seen between body mass index (BMI) and anovulation. Because we used
trained study personnel to measured the participant’s height and weight at baseline, using
the same equipment for everyone, the likelihood that misclassification would occur is
minimal.
Nondifferential misclassification of the outcome could occur if we inaccurately
identify a woman with ovulation as anovulatory regardless of their BMI. If this did occur
it would underestimate our results. Cases of anovulation are identified from lab values
obtained during the study period. The laboratory coefficient of variance, a measure of
reliability, for both LH and progesterone was small therefore reducing this concern (41,
41, 42, 42). We also are using two measures to confirm the presence of anovulation, both
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low progesterone levels and missing or late LH elevations. Therefore we feel that there is
little chance for misclassification to occur.
Due to the methodology of a prospective study there is little chance for selection
bias to occur, because the exposure of BMI is measured before the outcome of an
anovulatory cycle has happened. There is a chance for loss to follow-up to introduce bias
into a prospective study. This can occur if women lost to follow-up were more likely to
be in the high BMI group and also more likely to be anovulatory. If this were to happen it
would cause an underestimation of the true relative risk. Because of the asymptomatic
nature of anovulation we believe that the 17 participants who dropped out of the study
before one cycle was completed did not systematically differ by exposure or outcome and
that, therefore selection bias was unlikely to occur.
Prospective studies can face information bias when the diseased group of the
study is measured more carefully for exposure, or when the exposed group is questioned
differently than the unexposed for outcome information. An example of this is if those
with anovulation had more study visits measuring BMI than those ovulatory cycles or if
the samples provided by those with high BMI were checked more carefully for
anovulation. If this did happen we may find more cases of anovulation among those in
the high BMI category and this would bias our results by away from the null. Laboratory
workers were blinded to the participant’s exposure information making it very unlikely
that information bias would be present in our study.
We chose covariates to analyze for confounding based on their presence in
previous literature and their effects on statistical models. We are not aware of any key
confounding factors that were not measured during the study process. It is possible that
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there could be some residual confounding if key factors were not measured accurately.
An example of this would be looking at physical activity as a confounder. In our study
this measure was based on self report and if this was not reported accurately, even after
we adjust for it there would still be some confounding effect in the results. Because
physical activity is inversely associated with BMI and positively associated with
anovulation, failure to control this completely would result in an underestimation of the
true relative risk. We believe that any residual confounding would not affect our results
significantly.
Our study was limited to women with regular menstrual cycle length and we
believe that the results of our study may be generalized to all women with normal
menstrual cycle length. This is true because the biological mechanism through which
BMI impacts anovulation may differ among women with abnormal menstrual cycles.
In conclusion, we found no significant relationship between BMI and anovulation
among women with regular menstrual cycles. It is possible that some biases may have
occurred in this study but we feel that they are minimal and any that do occur would bias
our results towards the null and would underestimate the true association. The
relationship between BMI and anovulation among women with regular menstrual cycles
still remains unclear and there is need for further research. Studies with larger
populations that are not so restrictive to the exposure of BMI may have different results,
and should be conducted before concluding that BMI has no true association with
anovulation among women with regular menstrual cycles.
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TABLES
Table 1. Population Characteristics; BioCycle Study 2005-2007.
Overall
N=259
Demographics
Age (years): mean ± SD
27.29 ± 8.2
Current Smoker: n(%)
No
200 (78.7)
Yes
54 (21.3)
Missing
5
Current Alcohol use: n(%)
No
85 (33.0)
Yes
172 (66.9)
Missing
2
Perceived Stress Score: n(%)
Q1(7-18)
78 (30.2)
Q2(19-22)
64 (24.8)
Q3(23-25)
55 (21.3)
Q4(26-40)
61 (23.6)
Missing
1
Race: n(%)
White
154 (59.5)
Black
51 (19.7)
Other
54 (20.9)
Education Level: n(%)
High School Graduate or Less
33 (12.7)
Some College
101 (39)
College Graduate and Above
125 (48.3)
Physical Activity: n(%)
Low
25 (9.7)
Moderate
92 (35.5)
High
142 (54.8)
Previous Pregnancy: n(%)
No
111 (58.7)
Yes
78 (41.3)
Missing
70
Past OC use: n(%)
No
115 (45.1)
Yes
140 (54.9)
Missing
4
Measures of adiposity
BMI, (kg/m2): mean ± SD

24.08 ± 3.9

BMI, (kg/m2) Quartiles: n(%)
Q1 (16.4-21.0)
Q2 (21.1-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)
Waist to hip ratio (cm): mean ± SD
% Body Fat: mean ± SD
% Truncal Fat: mean ± SD
Truncal/Leg Fat: mean ± SD
Total skinfold thickness (mm): mean ± SD
Measures of Anovulation
Anovulation: n(%)
No
Yes
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65 (25.1)
65 (25.1)
65 (25.1)
64 (24.7)
0.75 ± 0.06
29.54 ± 5.99
25.11 ± 7.39
0.71 ± 0.15
81.18 ± 22.14

225 (86.9)
34 (13.1)

Table 2a. Correlation coefficients between measures of adiposity; BioCycle Study 2005-2007*.

Total Skinfold Thickness
Truncal/Leg Fat
Waist to Hip Ratio
% Truncal Fat
% Body Fat
BMI Quartile
BMI

BMI
0.75
0.66
0.33
0.79
0.75
0.92
1

BMI Quartile % Body Fat
0.69
0.75
0.66
0.62
0.34
0.22
0.75
0.95
0.7
1
1

*All p values were <.0001
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Total
% Truncal Waist to Hip Truncal/Leg Skinfold
Fat
Ratio
Fat
Thickness
0.77
0.3
0.6
1
0.84
0.49
1
0.35
1
1

Table 2b. Distribution of covariates according to BMI kg/m2 quartiles; BioCycle Study 2005-2007.
BMI Q1
BMI Q2
BMI Q3
BMI Q4
1
(16.1-21.0)
(21.0-23.5)
(23.6-26.2)
(26.3-35.0) P Value
Demographics
Age: mean ± SD
25.9 ± 7.3
26.2 ± 8.00
27.5 ± 8.6
29.6 ± 8.7
0.04
Current Smoker: n(%)
0.57
No
54 (84.4)
50 (79.4)
48 (76.2)
48 (75.0)
Yes
10 (15.6)
13 (20.6)
15 (23.8)
16 (25.0)
Missing (5)
Current Alcohol use: n(%)
0.85
No
24 (36.9)
22 (33.9)
19 (30.2)
20 (31.3)
Yes
41 (63.1)
43 (66.1)
44 (69.8)
44 (68.8)
Missing (2)
Perceived Stress Score: n(%)
0.98
Q1(7-18)
22 (33.9)
19 (29.7)
18 (27.7)
19 (29.7)
Q2(19-22)
16 (24.6)
16 (25.0)
19 (29.2)
13 (20.3)
Q3(23-25)
11 (16.9)
14 (21.9)
14 (21.5)
16 (25.0)
Q4(26-40)
16 (24.6)
15 (23.4)
14 (21.5)
16 (25.0)
Missing (1)
Race: n(%)
0.25
White
36 (55.4)
43 (66.2)
37 (56.9)
38 (59.4)
Black
12 (18.46)
7 (10.8)
15 (23.1)
17 (26.6)
Other
17 (26.15)
15 (23.1)
13 (20.0)
9 (14.1)
Education Level: n(%)
0.35
High School Graduate or Less
8 (12.3)
7 (10.8)
6 (9.2)
12 (18.8)
Some College
21 (32.3)
28 (43.1)
31 (47.7)
21 (32.8)
College Graduate and Above
36 (55.4)
30 (46.2)
28 (43.1)
31 (48.4)
Physical Activity: n(%)
0.84
Low
8 (12.3)
4 (6.2)
8 (12.3)
5 (7.8)
Moderate
24 (36.9)
24 (36.9)
23 (35.4)
21 (32.8)
High
33 (50.8)
37 (56.9)
34 (52.3)
38 (59.4)
Previous Pregnancy: n(%)
0.33
No
27 (64.3)
30 (63.8)
30 (60.0)
24 (48.0)
Yes
15 (35.7)
17 (36.2)
20 (40.0)
26 (52.0)
Missing (70)
Past OC use: n(%)
0.72
No
31 (50.8)
29 (44.6)
29 (44.6)
26 (40.6)
Yes
30 (49.2)
36 (55.4)
36 (55.4)
38 (59.4)
Missing (4)
Measures of adiposity
Waist to hip ratio (cm): mean ± SD
0.78 ± 0.04
0.74 ± 0.05
0.77 ± 0.07
0.77 ± 0.05
<.0001
% Body Fat: mean ± SD
24.9 ± 4.0
26.3± 4.5
31.5 ± 3.8
35.6 ± 4.5
<.0001
% Truncal Fat: mean ± SD
18.9 ± 4.5
21.0 ± 4.9
27.5 ± 4.9
33.0 ± 5.1
<.0001
Truncal/Leg Fat: mean ± SD
0.59 ± 0.10
0.64± 0.10
0.76 ± 0.13
0.85± 0.12
<.0001
Total skinfold thickness (mm): mean ± SD
63.2 ± 12.8
72.3 ± 14.2
86.1 ± 13.4
104.6 ± 21.9 <.0001
Measures of Anovulation
Anovulation: n(%)
0.23
No
53 (81.5)
56 (86.2)
56 (86.2)
60 (93.8)
Yes
12 (18.5)
9 (13.9)
9 (13.9)
4 (6.3)
1

P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests for Continuous variables
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Table 2c. Distribution of covariates according to % Body fat by DXA scan quartiles; BioCycle Study 2005-2007.
% Body Fat Q1 % Body Fat Q2 % Body Fat Q3 % Body Fat Q4
(15.10-24.65)
(24.66-29.81)
(29.82-33.53)
(33.54-45.25) P Value1
Demographics
Age: mean ± SD
26.4 ± 7.7
25.8 ± 7.8
27.5 ± 8.9
30.1 ± 8.0
0.02
Current Smoker: n(%)
0.83
No
46 (75.4)
49 (80.3)
47 (78.3)
50 (82.0)
Yes
15 (24.6)
12 (19.7)
13 (21.7)
11 (18.0)
Missing (16)
Current Alcohol use: n(%)
0.57
No
17 (27.4)
20 (32.3)
23 (37.7)
23 (37.7)
Yes
45 (72.6)
42 (67.7)
38 (62.3)
38 (62.3)
Missing (13)
Perceived Stress Score: n(%)
0.36
Q1(7-18)
16 (26.2)
25 (40.3)
16 (25.8)
16 (25.8)
Q2(19-22)
20 (32.8)
11 (17.7)
16 (25.8)
15 (24.2)
Q3(23-25)
10 (16.4)
15 (24.2)
12 (19.4)
17 (27.4)
Q4(26-40)
15 (24.6)
11 (17.7)
18 (29.0)
14 (22.6)
Missing (12)
Race: n(%)
0.79
White
38 (61.3)
39 (62.9)
35 (56.5)
35 (56.5)
Black
14 (22.6)
10 (16.1)
11 (17.7)
15 (24.2)
Other
10 (16.1)
13 (21.0)
16 (25.8)
12 (19.4)
Missing (11)
Education Level: n(%)
0.33
High School Graduate or Less
7 (11.3)
6 (9.7)
6 (9.7)
13 (21.0)
Some College
23 (37.1)
28 (45.2)
26 (41.9)
18 (29.0)
College Graduate and Above
32 (51.6)
28 (45.2)
30 (48.4)
31 (50.0)
Missing (11)
Physical Activity: n(%)
0.6
Low
4 (6.5)
8 (12.9)
3 (4.8)
7 (11.3)
Moderate
20 (32.3)
21 (33.9)
25 (40.3)
24 (38.7)
High
38 (61.3)
33 (53.2)
34 (54.8)
31 (50.0)
Missing (11)
Previous Pregnancy: n(%)
0.06
No
27 (58.7)
32 (72.7)
25 (56.8)
21 (44.7)
Yes
19 (41.3)
12 (27.3)
19 (43.2)
26 (55.3)
Missing (78)
Past OC use: n(%)
0.39
No
27 (44.3)
32 (52.5)
29 (46.8)
23 (37.1)
Yes
34 (55.7)
29 (47.5)
33 (53.2)
39 (62.9)
Missing (13)
Measures of adiposity
BMI, (kg/m2 ): mean ± SD
BMI, (kg/m2 ) Quartiles: n(%)
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)
Missing (11)
Waist to hip ratio (cm): mean ± SD
% Truncal Fat: mean ± SD
Truncal/Leg Fat: mean ± SD
Total skinfold thickness (mm): mean ± SD
Measures of Anovulation
Anovulation: n(%)
No
Yes
Missing (11)
1

21.14 ± 1.75

22.11 ± 2.57

24.89 ± 2.75

28.25 ± 3.65

30 (48.4)
27 (43.6)
5 (8.1)
0 (0.0)

27 (43.6)
19 (30.7)
10 (16.1)
6 (9.7)

5 (8.1)
13 (21.0)
26 (41.9)
18 (29.0)

1 (1.6)
3 (4.8)
19 (30.7)
39 (62.9)

0.74 ± 0.04
16.3 ± 2.6
0.58 ± 0.09
60.9 ± 11.2

0.74 ± 0.04
22.1 ± 2.7
0.66 ± 0.13
77.9 ± 15.0

0.76± 0.06
27.8 ± 3.1
0.77 ± 0.13
84.5 ± 14.7

0.77 ± 0.07
34.2 ± 4.1
0.83 ± 0.12
103.9 ± 22.5

54 (87.1)
8 (12.9)

52 (83.9)
10 (16.1)

56 (90.3)
6 (9.7)

59 (95.2)
3 (4.8)

<.0001
<.0001

0.0006
<.0001
<.0001
<.0001
0.22

P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests for Continuous variables
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Table 3. Distribution of covariates according to anovulation status; BioCycle Study
2005-2007.
Ovulatory
Demographics
Age: mean ± SD
Current Smoker: n(%)
No
Yes
Missing
Current Alcohol use: n(%)
No
Yes
Missing
Perceived Stress Score: n(%)
Q1(7-18)
Q2(19-22)
Q3(23-25)
Q4(26-40)
Missing
Race: n(%)
White
Black
Other
Education Level: n(%)
High School Graduate or Less
Some College
College Graduate and Above
Physical Activity: n(%)
Low
Moderate
High
Previous Pregnancy: n(%)
No
Yes
Missing
Past OC use: n(%)
No
Yes
Missing
Measures of adiposity
BMI, (kg/m2 ): mean ± SD
BMI, (kg/m2 ) Quartiles: n(%)
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)
Waist to hip ratio (cm): mean ± SD
% Body Fat: mean ± SD
% Truncal Fat: mean ± SD
Truncal/Leg Fat: mean ± SD
Total skinfold thickness (mm): mean ± SD

Anovulatory

P-Value

1

b

N=225
28.3 ± 8.3

N=34
20.8 ± 2.9

173 (78.6)
47 (21.4)
5

27 (79.4)
7 (20.6)
0

73 (32.7)
150 (67.3)
2

12 (35.3)
22 (64.7)
0

67 (29.9)
54 (24.1)
48 (21.4)
55 (24.6)
1

11 (32.4)
10 (29.4)
7 (20.6)
6 (17.7)
0

136 (60.4)
43 (19.11)
46 (20.4)

18 (52.9)
8 (23.5)
8 (23.5)

28 (12.4)
79 (35.1)
118 (52.4)

5 (14.7)
22 (64.7)
7 (20.6)

23 (10.2)
81 (36.0)
121 (53.8)

2 (5.9)
11 (32.4)
21 (61.8)

99 (56.6)
76 (43.4)
50

12 (85.7)
2 (14.3)
20

95 (42.6)
128 (57.4)

20 (62.5)
12 (37.5)

24.2± 3.9

25.0± 3.4

53 (23.6)
56 (24.9)
56 (24.9)
60 (26.7)
0.75 ± 0.06
29.8 ± 6.1
25.4 ± 7.5
0.71 ± 0.15
81.9 ± 23.1

12 (35.3)
9(26.5)
9 (26.5)
4 (11.8)
0.75 ± 0.04
27.7 ± 4.8
23.0 ± 6.1
0.69 ± 0.16
76.4 ± 14.2

< 0.001
0.92

0.78

0.80

0.70

< 0.001

0.65

0.04

0.03

0.08
0.23

1

0.57
0.08
0.12
0.67
0.18

P-values obtained from chi-square tests or Fishers exact for categorical variables and T-Tests
for Continuous variables
b
At least one anovulatory cycle. 24 women had 1 anovulatory cycle and 10 had 2 anovulatory
cycles. Total of 44 anovulatory cycles out of 509 in the study.

32

Table 4. Odds ratios and 95% CI of anovulation by baseline adiposity measures; BioCycle Study
Cases
BMI Quartiles
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)

N

%

12
9
9
4

35.3
26.5
26.5
11.8

Continuous BMI
%Body Fat Quartiles
Q1 (15.1-24.7)
Q2 (24.8-29.8)
Q3 (29.9-33.5)
Q4 (33.6-44.3)
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%Body Fat Continuous
%Truncal Fat Quartiles
Q1 (10.6-19.0)
Q2 (19.1-24.8)
Q3 (24.9-30.9)
Q4 (31.0-45.0)

27

%Truncal Fat Continuous
Truncal/Leg Fat Quartiles
Q1 (.364-.590)
Q2 (.591-.705)
Q3 (.706-.801)
Q4 (.802-1.14)

27

Truncal/Leg Fat Continuous
Waist to Hip ratio Quartiles
Q1 (.60-.717)
Q2 (.718-.746)
Q3 (.747-.781)
Q4 (.782-1.16)

27

Waist to Hip ratio Continuous
Total Skinfold Thickness Quartiles
Q1 (32.8-66.0)
Q2 (66.1-78.0)
Q3 (78.1-94.0)
Q4 (94.1-156.5)

34

Total Skinfold Thickness Continuous

34

1

8
10
6
3

10
6
8
3

8
5
7
7

6
12
9
7

9
11
10
4

3.23
4.03
2.42
1.21

4.03
2.42
3.23
1.21

3.23
2.02
2.82
2.82

2.34
4.69
3.52
2.73

3.53
4.31
3.92
1.57

Multivariable model adjusted for age.
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1

Unadjusted
OR
95% CI

Multivariable
OR
95% CI

1.00
0.71
0.71
0.29

Referent
(.28-1.82)
(.28-1.82)
(.090-0.99)

1.00
0.66
0.73
0.38

Referent
(.24-1.80)
(.26-2.01)
(.106-1.33)

0.91

(0.82-1.01)

0.93

(0.83-1.04)

1.00
1.3
0.72
0.34

Referent
(.475-3.55)
(.235-2.22)
(.087-1.36)

1.00
1.05
0.69
0.54

Referent
(.36-3.10)
(.21-2.29)
(.13-2.32)

0.941

(.878-1.01)

0.96

(.89-1.03)

1.00
0.56
0.77
0.26

Referent
(.189-1.64)
(.282-2.10)
(.069-1.01)

1.00
0.38
0.83
0.39

Referent
(.11-1.20)
(.28-2.49)
(.09-1.64)

0.956

(.903-1.01)

0.97

(.91-1.04)

1.00
0.592
0.859
0.859

Referent
(.182-1.92)
(.291-2.53)
(.291-2.53)

1.00
0.58
0.77
1.34

Referent
(.17-2.02)
(.24-2.45)
(.41-4.41)

0.581

(.040-8.37)

1.14

(.06-22.17)

1.00
2.15
1.5
1.21

Referent
(.754-6.14)
(.501-4.49)
(.382-3.83)

1.00
1.75
2.01
1.84

Referent
(.58-5.22)
(.63-6.43)
(.54-6.26)

0.127 (<.001-136.09)

5.01

(.003-999.99)

1.00
1.39
1.22
0.437

Referent
(.533-3.62)
(.459-3.22)
(.127-1.50)

1.00
1.19
1.37
0.59

Referent
(.43-3.29)
(.48-3.92)
(.16-2.16)

0.988

(.971-1.01)

0.99

(.97-1.02)

Table 5. Characteristic of women younger than 22 years; BioCycle Study 2005-2007.
All
Ovulatory
Anovulatory
BMI
Q1 (16.1-21.0)
22 (24.18)
14 (21.5)
8 (30.8)
Q2 (21.0-23.5)
27 (29.67)
19 (29.2)
8 (30.8)
Q3 (23.6-26.2)
25 (27.47)
17 (26.2)
8 (30.8)
Q4 (26.3-35.0)
17 (18.68)
15 (23.1)
2 (7.7)
Time since menarche (TSM)
3
4
5
6
7
8
9
10
Missing
Age
18
19
20
21
Odds Ratio for anovulation

1 (1.11)
2 (2.22)
9 (10.00)
13 (14.44)
20 (22.22)
21 (23.33)
14 (15.56)
10 (11.11)
1

0 (0.00)
0 (0.00)
5 (7.8)
9 (14.1)
16 (25.0)
14 (21.9)
11 (17.2)
9 (14.1)

1 (3.4)
2 (7.7)
4 (15.4)
4 (30.77)
4 (15.4)
7 (26.9)
3 (11.5)
1 (3.9)

9 (9.89)
30 (32.97)
34 (37.36)
18 (19.78)

5 (7.7)
23 (35.4)
23 (35.4)
14 (21.5)

4 (15.4)
7 (26.9)
11 (42.3)
4 (15.4)
Unadjusted
95% CI
(.51-.94)

OR
0.69

TSM Continuous
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Table 6. Characteristics of women 22 years and older; BioCycle Study 2005-2007.
All
Ovulatory
Anovulatory
BMI
Q1 (16.1-21.0)
43 (25.60)
39 (24.4)
4 (50.0)
Q2 (21.0-23.5)
38 (22.62)
37 (23.1)
1 (12.5)
Q3 (23.6-26.2)
40 (23.81)
39 (24.4)
1 (12.5)
Q4 (26.3-35.0)
47 (27.98)
45 (28.1)
2 (25.0)
Time since menarche (TSM)
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Missing
Odds Ratio for anovulation
TSM Continuous

0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (.61)
14 (8.48)
8 (4.85)
11 (6.67)
14 (8.48)
9 (5.45)
8 (4.85)
11 (6.67)
3 (1.82)
4 (2.42)
2 (1.21)
4 (2.42)
4 (2.42)
3 (1.82)
7 (4.24)
5 (3.03)
5 (3.03)
9 (5.45)
4 (2.42)
6 (3.64)
8 (4.85)
6 (3.64)
10 (6.06)
4 (2.42)
4 (2.42)
1 (.61)
3

0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
11 (6.9)
8 (5.0)
11 (6.9)
13 (8.2)
9 (5.7)
8 (5.0)
11 (6.9)
3 (1.9)
4 (2.5)
1 (0.6)
4 (2.5)
4 (2.5)
3 (1.9)
7 (4.4)
5 (3.1)
5 (3.1)
9 (5.7)
4 (2.5)
6 (3.8)
8 (5.0)
6 (3.8)
10 (6.3)
4 (2.5)
4 (2.5)
1 (0.6)

0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (16.7)
3 (50.0)
0 (0.00)
0 (0.00)
1 (16.7)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (16.7)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)

Unadjusted
OR
95% CI
0.71
(.50-1.00)
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Table 7. Age stratified results for association between BMI and anovulation; BioCycle Study 2005-2007.
Unadjusted
OR
95% CI
Where age < 22
N
BMI Quartiles
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)
Continuous BMI
1

Multivariable 1
OR
95% CI

91

26

1.00 Referent
0.74 (.222-2.44)
0.82 (.246-2.76)
0.23 (.042-1.29)

1.00
0.82
0.86
0.23

Referent
(.238-2.79)
(.255-2.91)
(.048-1.40)

0.89 (.763-1.04)

0.89

(.763-1.04)

8 (30.8)
8 (30.8)
8 (30.8)
2 (7.7)

Multivariable model adjusted for age.

Unadjusted
OR
95% CI
Where age ≥ 22
N

Multivariable 1
OR
95% CI

168

Anovulation
Frequency
8

BMI Quartiles
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)

1.00
0.26
0.25
0.43

Referent
(.028-2.47)
(.027-2.34)
(.075-2.50)

1.00
0.27
0.35
0.79

Referent
(.028-2.65)
(.035-3.39)
(.126-4.91)

Continuous BMI

0.94

(.781-1.14)

0.99

(.821-1.91)

1

Anovulation
Frequency n(%)

Multivariable model adjusted for age.
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4 (50.0)
1 (12.5)
1 (12.5)
2 (25.0)

Table 8. BMI distributed by quintiles and sextiles; BioCycle Study 2005-2007.
Ovulatory Anovulatory
BMI, (kg/m2) Quintiles: n(%)
Q1 (16.14-20.47)
Q2 (20.48-22.61)
Q3 (22.62-24.43)
Q4 (24.44-27.03)
Q5 (27.04-34.98)

42 (18.7)
44 (19.6)
46 (20.4)
46 (20.4)
47 (20.9)

10 (29.4)
8 (23.5)
6 (17.7)
6 (17.7)
4 (11.8)

BMI, (kg/m2) Sextiles: n(%)
Q1 (16.14-20.21)
Q2 (20.22-22.12)
Q3 (22.13-23.46)
Q4 (23.47-25.07)
Q5 (25.08-27.97)
Q6 (27.98-34.98)

36 (16.0)
34 (15.1)
39 (17.3)
38 (16.9)
39 (17.3)
39 (17.3)

8 (23.5)
9 (26.5)
4 (11.8)
5 (14.7)
4 (11.8)
4 (11.8)

Unadjusted
OR
95% CI
BMI Quintiles
Q1 (16.14-20.47)
Q2 (20.48-22.61)
Q3 (22.62-24.43)
Q4 (24.44-27.03)
Q5 (27.04-34.98)
BMI Sextiles
Q1 (16.14-20.21)
Q2 (20.22-22.12)
Q3 (22.13-23.46)
Q4 (23.47-25.07)
Q5 (25.08-27.97)
Q6 (27.98-34.98)

Multivariable 1
OR
95% CI

1.00
0.76
0.55
0.55
0.36

Referent
(.275-2.12)
(.183-1.64)
(.183-1.64)
(.104-1.23)

1.00
0.87
0.522
0.621
0.53

Referent
(.291-2.60)
(.163-1.67)
(.192-2.01)
(.141-1.99)

1.00
1.19
0.46
0.59
0.46
0.46

Referent
(.412-3.44)
(.128-1.67)
(.177-1.98)
(.128-1.67)
(.128-1.67)

1.00
1.204
0.358
0.523
0.616
0.507

Referent
(.376-3.85)
(.093-1.38)
(.143-1.92)
(.154-2.47)
(.127-2.02)
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Table 9. Odds ratios and 95% CI of anovulation per cycle by
adiposity measures: BioCycle Study 2005-2007
Unadjusted
OR
95% CI

Multivariable 1
OR
95% CI

1.00
0.67
0.66
0.20

Referent
(0.256-1.73)
(0.254-1.70)
(0.063-0.650)

1.00
0.65
0.67
0.26

Referent
(0.243-1.71)
(0.251-1.77)
(0.075-1.15)

Continuous BMI
%Body Fat Quartiles
Q1 (15.1-24.7)
Q2 (24.8-29.8)
Q3 (29.9-33.5)
Q4 (33.6-44.3)

0.89

(0.805-0.98)

0.90

(0.803-1.01)

1.00
1.69
0.98
0.28

Referent
(0.611-4.67)
(0.251-2.49)
(0.073-1.10)

1.00
1.35
0.76
0.44

Referent
(0.466-3.90)
(0.246-2.35)
(0.103-1.90)

%Body Fat Continuous

0.94

(0.889-0.985)

0.95

(0.895-1.01)

BMI Quartiles
Q1 (16.1-21.0)
Q2 (21.0-23.5)
Q3 (23.6-26.2)
Q4 (26.3-35.0)
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